tasquinimod
Tasquinimod is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant or hormone-refractory prostate cancer, is prostate cancer that grows despite medical or surgical androgen deprivation therapy. Tasquinimod targets the tumor microenvironment and counteracts cancer development by inhibiting angiogenesis and metastasis and by modulating the immune system. It is now in phase III development, following successful phase II trial outcomes. — Wikipedia
Clinical trial activity
12 trials · 10 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2007 (NCT00560482)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Fibrosis · Phase 2
- Healthy Volunteers · Phase 1
- Multiple Myeloma · Phase 1
- Ovarian Neoplasms · Phase 2
- Polycythemia Vera · Phase 2
- Primary Myelofibrosis · Phase 2
- Prostatic Neoplasms · Phase 3
- Prostatic Neoplasms, Castration-Resistant · Phase 3
- Stomach Neoplasms · Phase 2
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
SMILES
COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C- Mol. weight
- 406.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTasquinimod ↗
- ChEMBLCHEMBL2107784 ↗
Also known as
- 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-((4-trifluoromethyl)phenyl)-1,2-dihydroquinoline-3-carboxamide
- abr-215050
- tasq
- tasq
- tasquinimod
- tasquinimod
- tasquinimod
- tasquinimod
- tasquinimod
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06605586 | Phase 1/Phase 2 (Phase 2) | Oct 15, 2024 | Erasmus University Rotterdam, HOVON - Dutch Haemato-Oncology Association |
| NCT06327100 | Phase 2 | Aug 1, 2024 | Active Biotech AB, University of Texas at Houston |
| NCT04405167 | Phase 1 | Jun 1, 2020 | Active Biotech AB, University of Pennsylvania |
| NCT02396368 | Phase 1 | Mar 1, 2015 | Johns Hopkins University |
| NCT02159950 | Phase 2 | Jan 1, 2015 | Active Biotech AB, National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT02057666 | Phase 3 | Jan 1, 2014 | Ipsen |
| NCT01732549 | Phase 2 | Jan 1, 2013 | Ipsen |
| NCT01743469 | Phase 2 | Dec 1, 2012 | Ipsen |
| NCT01513733 | Phase 1 | Jan 1, 2012 | Duke University |
| NCT01234311 | Phase 3 | Mar 1, 2011 | Active Biotech AB, Johns Hopkins University |
| NCT01048203 | Phase 1 | Jan 1, 2009 | Active Biotech AB |
| NCT00560482 | Phase 2 | Dec 1, 2007 | Active Biotech AB, State University of New York, Buffalo |
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Active Biotech AB | For profit | 6 | 3 | 3 | 2007 |
| Ipsen | For profit | 3 | 3 | 2 | 2012 |
| Johns Hopkins University | Academic/Hospital | 2 | 1 | 2 | 2011 |
| State University of New York, Buffalo | Academic/Hospital | 2 | 1 | 1 | 2007 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2024 |
| HOVON - Dutch Haemato-Oncology Association | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2024 |